The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale

详细信息    查看全文

• 作者：Michael B. Saddekni^a ; Kenneth G. Saag^a ; Tanja Dudenbostel^b ; Suzanne Oparil^b ; David A. Calhoun^b ; Sebastian E. Sattui^c ; Daniel I. Feig^d ; Paul Muntner^e ; David T. Redden^f ; Phillip J. Foster^a ; Elizabeth J. Rahn^a ; Stephanie R. Biggers^a ; Peng Li^f ; Angelo L. Gaffo^a ; ^{agaffo@uabmc.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：AAs ; African Americans ; ABPM ; ambulatory blood pressure monitoring ; AEs ; adverse events ; AHS ; allopurinol hypersensitivity syndrome ; BP ; blood pressure ; CoRT ; Center of Research Translation in Gout and Hyperuricemia ; CRP ; C-reactive protein ; CV ; cardiovascular ; DBP ; diastolic blood pressure ; DSMB ; Data Safety and Monitoring Board ; FMD ; flow-mediated dilation ; GCP ; Good Clinical Practice ; GRF ; glomerular filtration rate ; hsCRP ; high sensitivity C-reactive protein ; IRB ; Institutional Review Board
• 刊名：Contemporary Clinical Trials
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：50
• 期：Complete
• 页码：238-244
• 全文大小：378 K

文摘

The association between hyperuricemia and hypertension is controversial. Animal models, epidemiological data, and small clinical trials have favored a causative role for hyperuricemia in hypertension but more studies are necessary to elucidate putative mechanisms, population susceptibility, and potential for urate-lowering therapies (ULT) to decrease blood pressure (BP).

Purpose

To describe the background and design of the Serum Urate Reduction to Prevent Hypertension (SURPHER) study.

Methods

SURPHER is a single center, double-blinded, crossover trial in which participants are randomly assigned to allopurinol (300 mg) or placebo. Enrollment focused on adults 18–40 years old with baseline systolic blood pressure ≥ 120 and < 160 mm Hg or diastolic blood pressure ≥ 80 and < 100 mm Hg, and serum urate ≥ 5.0 mg/dL or ≥ 4.0 mg/dL for men or women, respectively. SURPHER recruitment targets participants without chronic kidney disease (estimated glomerular filtration rate > 60 mL/min/1.73 m2), and without prior diagnosis of gout or use of ULT to treat gout. The primary outcome is change from baseline in blood pressure assessed by 24 hour ambulatory blood pressure monitoring and mechanistic outcomes include changes in endothelial function as measured by flow-mediated dilation, as well as C-reactive protein levels.

Results

Since June 16, 2014 until present, SURPHER is recruiting participants in the city of Birmingham, Alabama.

Limitations

The study aims to enroll otherwise healthy young adults for a pharmacological intervention study with multiple study-related procedures. Challenges related to recruitment are anticipated and multiple strategies for increasing recruitment and retention are planned if necessary.